News

The American Journal of Managed Care1d

Brensocatib Becomes First FDA-Approved Therapy for Bronchiectasis

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with ...
Healio1d

FDA approves brensocatib for non-cystic fibrosis bronchiectasis

The FDA granted approval to brensocatib for treating adults and children aged at least 12 years with non-cystic fibrosis ...

PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...
HealthDay on MSN10h

First drug to treat bronchiectasis lung condition approved by FDA

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under ...

FDA approves first drug for chronic lung condition bronchiectasis

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...
MedPage Today on MSN1d

Serious Chronic Lung Disease Gets First FDA-Approved Drug

A first-in-class reversible dipeptidyl peptidase-1 (DPP-1) inhibitor, brensocatib addresses the underlying inflammatory ...

FDA Approves BRINSUPRITM (Brensocatib) As The First And Only Treatment For Non-Cystic Fibrosis Bronchiectasis, A Serious, Chronic Lung Disease

Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permane ...

NIH study links cigarette cessation with drug, alcohol addiction recovery

A new federal study is linking the ability to quit smoking with longer-term success from the grip of drug or alcohol ...
PharmExec1d

FDA Approves Insmed’s Brinsupri as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Brinsupri is a first-in-class DPP1 inhibitor that has been found to inhibit activation of neutrophil enzymes that drive chronic airway inflammation in non-cystic fibrosis bronchiectasis.
The Pharma Letter15h

FDA approves Brinsupri for chronic inflammatory lung condition

The US Food and Drug Administration approved New Jersey, USA-based Insmed’s (Nasdaq: INSM) fibrosis bronchiectasis (NCFB), a ...